^
    Contact us  to learn more about
    our Premium Content:  News alerts, weekly reports and conference planners
    DRUG:

    ET140203

    i
    Associations
    News

    Trials

    Company:
    Eureka Therap, JW (Cayman) Therap
    Drug class:
    Cytotoxic T lymphocyte stimulant, γδ TCR modulator, AFP inhibitor
    Related drugs:
    Associations
    News

    Trials

    Apply
    ET140203 T Cells in Pediatric Subjects With Hepatoblastoma, HCN-NOS, or Hepatocellular Carcinoma (ARYA-2) (NCT04634357)
    Phase 1/2
    Eureka Therapeutics Inc.
    Recruiting
    Last update posted :
    03/07/2024
    Initiation :
    07/19/2022
    Primary completion :
    01/31/2026
    Completion :
    01/31/2028
    AFP
    |
    ET140203